Last 540.00 GBp
Change Today 0.00 / 0.00%
Volume 408.9K
As of 11:35 AM 02/27/15 All times are local (Market data is delayed by at least 15 minutes).

clinigen group plc (CLIN) Snapshot

540.00 GBp
Previous Close
540.00 GBp
Day High
540.00 GBp
Day Low
534.50 GBp
52 Week High
11/14/14 - 570.50 GBp
52 Week Low
08/8/14 - 359.25 GBp
Market Cap
Average Volume 10 Days
0.20 GBp
Shares Outstanding
3.44 GBp
Dividend Yield
Current Stock Chart for CLINIGEN GROUP PLC (CLIN)

Related News

No related news articles were found.

clinigen group plc (CLIN) Related Businessweek News

No Related Businessweek News Found

clinigen group plc (CLIN) Details

Clinigen Group plc provides specialty pharmaceutical products and services in the United Kingdom and internationally. The company’s Clinical Trials Supply business provides commercial medicines for use in clinical and comparator trial drug sourcing. Its Specialty Pharmaceuticals business offers Cardioxane to prevent the chronic cumulative cardiotoxicity caused by doxorubicin or epirubicin use in advanced and/or metastatic adult breast cancer; Foscavir for the treatment of cytomegalovirus retinitis in HIV patients and Acyclovir-resistant mucocutaneous herpes simplex virus infections in immunocompromised patients, as well as cytomegalovirus-viremia and CMV disease in patients; Savene for the treatment of anthracycline extravasation; and VIBATIV, a bactericidal injectable lipoglycopeptide antibacterial antibiotic against Gram-positive bacteria, including resistant pathogens, such as methicillin-resistant Staphylococcus aureus. The company’s Global Access Programs business is involved in the consultancy, development, management, and implementation of access programs to manage access to unlicensed, licensed, or end-of-lifecycle products. It serves patients, pharmaceutical/biotechnology companies, and contract research organizations. The company is headquartered in Burton-on-Trent, the United Kingdom.

107 Employees
Last Reported Date: 10/9/14

clinigen group plc (CLIN) Top Compensated Officers

Chief Executive Officer and Executive Directo...
Total Annual Compensation: 590.0K GBP
Chief Financial Officer, Company Secretary an...
Total Annual Compensation: 346.0K GBP
Chief Operating Officer and Executive Directo...
Total Annual Compensation: 426.0K GBP
Compensation as of Fiscal Year 2014.

clinigen group plc (CLIN) Key Developments

Astrazeneca Appoints Clinigen Group plc to Manage International Global Access Program for New Combination Antibiotic, CAZ-AVI

Clinigen Group plc announced the initiation of an international global access program for AstraZeneca's investigational antibiotic, CAZ-AVI (ceftazidame-avibactam), through its specialist Clinigen GAP division. CAZ-AVI is being developed to treat a broad range of Gram-negative bacterial infections which are becoming resistant to antibiotics and pose an increasing risk to public health. It is being investigated as a new treatment option for patients with complicated urinary tract infections (cUTIs), complicated intra-abdominal infections (cIAIs) and nosocomial pneumonia. Complicated urinary tract and intra-abdominal infections are often attributed to drug-resistant bacteria. Gram-negative bacteria such as Escherichia coli (E. coli) are particularly adaptive.

Clinigen Group plc Announces Revenue Results for the Six Months Ended 31 December 2014

Clinigen Group plc announced revenue results for the six months ended 31 December 2014. For the period, the group continues to perform strongly, in line with the board's expectations. Revenues were £72.6 million up 17% on first half of fiscal year 2014 (21% on a constant exchange rate basis).

Clinigen Group Plc Presents at Jefferies 2014 Global Healthcare Conference: London, Nov-19-2014 12:20 PM

Clinigen Group Plc Presents at Jefferies 2014 Global Healthcare Conference: London, Nov-19-2014 12:20 PM. Venue: The Waldorf Hilton, Aldwych, London, United Kingdom.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CLIN:LN 540.00 GBp 0.00

CLIN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for CLIN.
View Industry Companies

Industry Analysis


Industry Average

Valuation CLIN Industry Range
Price/Earnings 25.6x
Price/Sales 3.2x
Price/Book 6.1x
Price/Cash Flow 24.8x
TEV/Sales 3.2x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CLINIGEN GROUP PLC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at